Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | TOURMALINE-MM3: undetectable MRD as an endpoint for maintenance therapy

Bruno Paiva • 12 Jun 2020
EHA 2020
Multiple Myeloma Ixazomib
TOURMALINE-MM3

Bruno Paiva, PhD, of the University of Navarra, Pamplona, Spain, discusses results from the TOURMALINE-MM3 study (NCT02181413) of ixazomib vs placebo maintenance therapy in newly diagnosed multiple myeloma patients. Interestingly, TOURMALINE-MM3 used undetectable minimal residual disease as the clinical endpoint for this trial. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Bruno Paiva

What is the most effective method for detecting circulating tumor cells in multiple myeloma? 1:40
What is the most effective method for detecting circulating tumor cells in multiple myeloma?
Bruno Paiva • 18 Sep 2025
Characterizing the genomics of CTCs to predict myeloma progression and stability 1:24
Characterizing the genomics of CTCs to predict myeloma progression and stability
Bruno Paiva • 18 Sep 2025
MRD dynamics and early immunotherapy interception in multiple myeloma 2:57
MRD dynamics and early immunotherapy interception in multiple myeloma
Bruno Paiva • 18 Sep 2025
Endogenous immune profiles linked to PFS in patients with RRMM treated with CAR T-cells 2:40
Endogenous immune profiles linked to PFS in patients with RRMM treated with CAR T-cells
Bruno Paiva • 18 Sep 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals